Brainsway jumps on US trial announcement
The company and the Veterans Administration Medical Center will conduct clinical trial of Deep TMS on adult patients with attention deficit disorder.
In its notice to the Tel Aviv Stock Exchange (TASE), Brainsway stated, "This trial is part of the company's strategy to conduct human clinical trials to test the effectiveness of the device for the treatment of a range of illnesses, in addition to depression and including Alzheimer's, and Parkinson's, and the treatment cannabis and cocaine addiction."
Brainsway is already conducting a number of clinical trials to test the effectiveness of Deep TMS. In April, it announced a trial with the US National Institute of Drug Abuse for treatment of cocaine addiction. The company is also testing the device as a cure for obesity.
Brainsway's share rose 7.8% to NIS 12.20 today.
Published by Globes [online], Israel business news - www.globes-online.com - on August 2, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options